CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

A study reveals that CRISPR gene editing can disable a mutation in melanoma cells that leads to treatment resistance. By targeting the NRAS gene mutation, researchers restored the cells' sensitivity ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

New gene therapies developed using CRISPR gene editing offer the promise of treating or even curing debilitating diseases.

Let's examine what this company is planning for the future, and figure out whether that makes its stock worth buying or not.

In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of ...

On The Readout LOUD, John Maraganore discusses his new startup, and STAT's Megan Molteni tells the latest about "CRISPR baby" ...

Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated ...

The Roslin Institute for Animal Research turns to gene editing to combat some of the most important diseases in livestock and ...